Karyopharm Therapeutics Inc. (NASDAQ:KPTI) price closed higher on Monday, September 13, jumping 3.45% above its previous close.
A look at the daily price movement shows that the last close reads $5.79, with intraday deals fluctuated between $5.685 and $6.135. The company’s 5Y monthly beta was ticking 0.20. Taking into account the 52-week price action we note that the stock hit a 52-week high of $18.00 and 52-week low of $4.42. The stock added 24.27% on its value in the past month.
Karyopharm Therapeutics Inc., which has a market valuation of $448.35 million, is expected to release its quarterly earnings report Nov 01, 2021 – Nov 05, 2021. Analysts tracking KPTI have forecast the quarterly EPS to shrink by -0.67 per share this quarter, while the same analysts predict the annual EPS to hit -$2.82 for the year 2021 and up to -$1.96 for 2022. In this case, analysts estimate an annual EPS growth of -3.70% for the year and 30.50% for the next year.
On average, analysts have forecast the company’s revenue for the quarter will hit $25.8 million, with the likely lows of $21.1 million and highs of $33.06 million. The average estimate suggests sales growth for the quarter will likely rise by 20.90% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $97.8 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow -9.50% below that which the company brought in 2021.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give KPTI a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 10 analysts have assigned KPTI a recommendation rating as follows: 3 rate it as a Hold; 4 advise Buy while 2 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Karyopharm Therapeutics Inc. (KPTI) stock as Underweight, with 1 recommending Sell. In general, analysts have rated the stock Overweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that KPTI’s price is at present 13.20% off the SMA20 and -16.46% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 50.37, with weekly volatility standing at 6.18%. The indicator jumps to 6.65% when calculated based on the past 30 days. Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s beta value is holding at 0.20, while the average true range (ATR) indicator is currently reading 0.39. Considering analysts have assigned the stock a price target range of $6.00-$29.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $15.22. Based on this estimate, we see that current price is roughly -0.17% off the estimated low and -384.14% off the forecast high. Investors will no doubt be excited to see the share price fall to $15.00, which is the median consensus price, and at that level KPTI would be -150.42% from current price.
Turning out attention to how the Karyopharm Therapeutics Inc. stock has performed in comparison to its peers in the industry, here’s what we find: KPTI’s stock is 3.45% on the day and -57.82% in the past 12 months, while Bristol-Myers Squibb Company (BMY) traded -0.46% in the last session and was positioned 6.53% up on its price 12 months ago. Another comparison is with Abbott Laboratories (ABT) whose stock price was down -1.69% in the last trading session, and has flourished 20.94% over the past year. Also, Exelixis Inc. (EXEL) showed up trend of 1.30% while its price kept floating at -6.95% over the past year. Elsewhere in the market, the S&P 500 Index has rallied 0.23% in last trading session, with the Dow Jones Industrial also saw a positive session on the day with 0.76%.
An analysis of the Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stock in terms of its daily trading volume indicates that the 3-month average is 1.49 million.
Current records show that the company has 75.19M in outstanding shares. The insiders’ percentage holdings are 2.90% of outstanding shares while the percentage share held by institutions stands at 80.50%. But the -61.30% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.